About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Ranbaxy Gets the Nod to Commence Distribution of Its Anti-malarial Drug in 7 African Countries

by Kalyani Thivakaran on December 16, 2014 at 4:28 PM
Font : A-A+

 Ranbaxy Gets the Nod to Commence Distribution of Its Anti-malarial Drug in 7 African Countries

The Indian multinational pharmaceutical company, Ranbaxy Laboratories has received regulatory nod to launch its indigenously developed anti-malarial drug, Synriam, in seven African countries. The company is going to be launching its first New Chemical Entity (NCE) Synriam in seven African countries namely Nigeria, Uganda, Senegal, Cameroon, Guinea, Kenya and Ivory Coast, said Ranbaxy Laboratories in a statement.

They further added that the product has already been launched in Uganda and will be made available in other six countries towards the end of January 2015. Ranbaxy CEO and MD Arun Sawhney said, "Most malaria cases and deaths occur in sub- Saharan Africa... Synriam is among the best options available today as it is highly effective, affordable and a convenient therapy option, leading to better compliance."

Advertisement

Mr. Sawhney also said that the company is confident that the drug will help the government and healthcare system in Africa to fight the menace of malaria. The new drug conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Commenting on the drug, Ranbaxy said that Synriam provides quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95 percent.

The dosage regimen for the product involves the patient taking just one tablet per day for three days, which is much simpler when compared to other medicines where two to four tablets are required to be taken, twice daily, for three or more days. The Ranbaxy spokesperson added, "Since Synriam has a synthetic source, unlike artemisinin based drugs, production can be scaled up whenever required and a consistent supply can be maintained at a low cost."
Advertisement

Ranbaxy had commenced the research on the drug in 2003 and received the Drug Controller General of India's (DCGI) approval in 2011 to manufacture and market it in India. The product is used for treatment of acute uncomplicated "Plasmodium falciparum malaria" in patients aged 12 years and above. The spokesperson further added that the company is also conducting Phase III clinical trials for the pediatric formulation of Synriam for usage in children suffering from the same problem.



Source: Medindia
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Tropical Disease News

Oral Cholera Vaccine Launched in India by Pharma Giants
Mumbai's TechInvention Lifecare and South Korean Eubiologics team up to introduce oral cholera vaccine in India after successful phase III clinical trial.
Evolving Threat of Dengue Virus in India
Scientists have found that the dengue virus has become more severe in India, highlighting the urgent need for vaccines that target the strains found in the country.
 Watch Out for Acute Kidney Disease as a Complication of Malaria
It is important to consider malarial infection in cases of acute kidney injury in someone with a travel history from endemic areas to improve treatment outcomes.
India's Malaria Vaccine Gets the Green Light for First Time in Ghana
Ghana approves the use of the University of Oxford's malaria vaccine, produced by the Serum Institute of India (SII), becoming the first country to adopt the new vaccine.
 Deadly Dengue Virus Hijacks Mosquito Saliva to Spread Sickness
The dengue virus combines molecules from its RNA with mosquito saliva to foil the human immune system and spread dengue fever and related diseases.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Ranbaxy Gets the Nod to Commence Distribution of Its Anti-malarial Drug in 7 African Countries Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests